Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Urszula A Sobol, MD, Tulio E. Rodriguez, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Ross Vimr, MD, Mala Parthasarathy, MS, Rong Guo, MS, Patrick Stiff, MD

Blood (2012) 120 (21): 3131.

https://doi.org/10.1182/blood.V120.21.3131.3131

Published: 2012

Journal Articles

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Michael Henry, BS, Rong Guo, MS, Mala Parthasarathy, MS, John Lopez, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3070.

https://doi.org/10.1182/blood.V120.21.3070.3070

Published: 2012

Journal Articles

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Brian Hess, MD, Matthew Siegel, MD, Tulio E. Rodriguez, MD, Shams Bakhos, MD, Maria Theodorou, Michael Tallarico, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3102.

https://doi.org/10.1182/blood.V120.21.3102.3102

Published: 2012

Journal Articles

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

James R. Cook, MD, PhD, Bryan H. Goldman, MS, Raymond R. Tubbs, DO, Michael LeBlanc, PhD, Lisa M. Rimsza, MD, Patrick Stiff, MD, Richard I Fisher, MD

Blood (2012) 120 (21): 543.

https://doi.org/10.1182/blood.V120.21.543.543

Published: 2012

Journal Articles

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Ranjana Advani, MD, Fangxin Hong, PhD, Leo I. Gordon, MD, FACP, Randy D. Gascoyne, MD, Henry Wagner, MD, Richard T. Hoppe, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Brad S. Kahl, MD, Patrick Stiff, MD, Bruce D. Cheson, MD, Andrew R Belch, MD, Jonathan W. Friedberg, MD, MMSc, Jeannine Kassis, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Sandra J. Horning, MD

Blood (2011) 118 (21): 1603.

https://doi.org/10.1182/blood.V118.21.1603.1603

Published: 2011

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience

Blood (2011) 118 (21): 3074.

https://doi.org/10.1182/blood.V118.21.3074.3074

Published: 2011

Journal Articles

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

H. Jean Khoury, MD, FACP, Robert H. Collins, Jr, MD, William Blum, MD, Lori Maness, MD, Patrick Stiff, MD, Stephen M. Kelsey, MD, Anita Reddy, PhD, Jennifer A. Smith, PhD, John F. DiPersio, MD, PhD

Blood (2010) 116 (21): 2190.

https://doi.org/10.1182/blood.V116.21.2190.2190

Published: 2010

Journal Articles

C-Myc Is Required for Acute but Not for Chronic Hematopoietic Malignances in Pten-Null Mice.

Yinshi Guo, MD, PhD, Christopher Seet, MBBS, Chao Niu, MD, PhD, Peter Breslin, PhD, Shubin Zhang, MD, Wei Wei, BS, Manuel Diaz, MD, Patrick Stiff, MD, Jiwang Zhang, MD, PhD

Blood (2009) 114 (22): 1632.

https://doi.org/10.1182/blood.V114.22.1632.1632

Published: 2009

Journal Articles

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Ivana N Micallef, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Frank J Hsu, MD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 2319.

https://doi.org/10.1182/blood.V114.22.2319.2319

Published: 2009

Journal Articles

Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.

Richard T. Maziarz, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 33.

https://doi.org/10.1182/blood.V114.22.33.33

Published: 2009

Journal Articles

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Brian J. Bolwell, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Richard T. Maziarz, MD, Ivana N Micallef, MD, Sachin Marulkar, MBBS, MPH, Pritesh Gandhi, PharmD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3224.

https://doi.org/10.1182/blood.V114.22.3224.3224

Published: 2009

Journal Articles

Phase III Randomized Stem Cell Mobilization Trial Comparing Standard Vs Double-Dose G-CSF Vs Standard Doses of G-CSF Plus GM-CSF in Hard to Mobilize Patients Undergoing An Autologous Hematopoietic Stem Cell Transplant (HSCT).

Elizabeth Berger, BA, Christopher Seet, MBBS, Mala Parthasarathy, MS, Tulio Rodriguez, MD, Scott E. Smith, MD, PhD, Amir Toor, MD, Mary Lee, RN, Cecilia Petrowsky, MSN, Mary Fox-Geiman, PharmD, Patrick Stiff, MD

Blood (2009) 114 (22): 3228.

https://doi.org/10.1182/blood.V114.22.3228.3228

Published: 2009

Journal Articles

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Auayporn P. Nademanee, MD, Edward Stadtmauer, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3230.

https://doi.org/10.1182/blood.V114.22.3230.3230

Published: 2009

Journal Articles

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Blood (2009) 114 (22): 43.

https://doi.org/10.1182/blood.V114.22.43.43

Published: 2009

Journal Articles

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

John F. DiPersio, MD, PhD, Robert H. Collins, Jr., MD, William Blum, MD, Marcel P Devetten, M.D., Patrick Stiff, MD, Laurence Elias, MD, Anita Reddy, Ph.D., Jennifer A. Smith, Ph.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 633.

https://doi.org/10.1182/blood.V114.22.633.633

Published: 2009

Journal Articles

Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.

Laura C Michaelis, MD, Danielle Shafer, DO, Kevin Barton, MD, Tulio Rodriguez, MD, Scott Smith, M.D., Ph.D, Patrick Stiff, MD, Sucha Nand, MD

Blood (2009) 114 (22): 1034.

https://doi.org/10.1182/blood.V114.22.1034.1034

Published: 2009

Journal Articles

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Patrick Stiff, MD, Mary Fox-Geiman, PharmD, Karen Kiley, MSN, NP, Nancy Porter, MSN, APN, Karen Rychlik, BA, Donna Fletcher-Gonzalez, PharmD, Amir Toor, MD, Scott E. Smith, MD, PhD, Tulio Rodriguez, MD

Blood (2009) 114 (22): 2267.

https://doi.org/10.1182/blood.V114.22.2267.2267

Published: 2009

Journal Articles

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Anjali Advani, MD, Holly Gundacker, MS, Olga Sala-Torra, MD, Jerald Radich, MD, Raymond Lai, MD, PhD, Marilyn L. Slovak, PhD, Jeffrey E Lancet, MD, Steve Coutre, MD, Robert K Stuart, MD, Martha P. Mims, MD, PhD, Patrick Stiff, MD, Frederick R. Appelbaum, MD

Blood (2009) 114 (22): 3094.

https://doi.org/10.1182/blood.V114.22.3094.3094

Published: 2009

Journal Articles

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Ricardo Spielberger, MD, Mary Territo, MD, Simon Durrant, MD, Stephen Nimer, MD, John McCarty, MD, David Hurd, MD, Dietmar Berger, MD, Jeff Aycock, Mon-Gy Chen, Patrick Stiff, MD

Blood (2007) 110 (11): 1664.

https://doi.org/10.1182/blood.V110.11.1664.1664

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Ivana Micallef, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, for the 3102 Investigators7

Blood (2007) 110 (11): 445.

https://doi.org/10.1182/blood.V110.11.445.445

Published: 2007

NARROW

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

C-Myc Is Required for Acute but Not for Chronic Hematopoietic Malignances in Pten-Null Mice.

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Phase III Randomized Stem Cell Mobilization Trial Comparing Standard Vs Double-Dose G-CSF Vs Standard Doses of G-CSF Plus GM-CSF in Hard to Mobilize Patients Undergoing An Autologous Hematopoietic Stem Cell Transplant (HSCT).

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only